Plain-English translation of NCT04311411 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested , a new medication, to see how it affected how much people ate and what parts of their brain controlled appetite and food cravings. Researchers used brain imaging scans to watch how the medication changed brain activity related to hunger and desire for food. The study compared this medication to a placebo (dummy injection) and to another existing medication to understand which worked best.
Obesity and being overweight affect millions of people, but current treatment options are limited. This trial was designed to understand exactly how this new medication works in the brain to reduce appetite and food intake, which could help doctors better treat weight-related conditions.
Participants attended up to 14 visits to the study center over about four months. At each visit, they received injections of either the new medication, a placebo, or another medication under the skin of their abdomen. The injections were given once a week for six weeks, with the dose gradually increasing. Participants also underwent brain imaging scans (called fMRI) to show how the medication changed activity in parts of the brain related to hunger and food reward.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States